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The finding that the HER2 receptor tyro-
sine kinase (RTK) is involved in breast
cancer was one of the first great bench-
to-bedside discoveries that originated
from the application of molecular
biology techniques to human cancer
(Slamon et al., 1989). Almost immedi-
ately, speculation in the prostate cancer
field turned toward HER2 as a potential
player in this solid tumor, which resem-
bles breast cancer in its hormone
dependence and in other physiological
features. Despite many studies of model
systems and clinical specimens span-
ning more than a decade, the role of
HER2 in prostate cancer—or whether
there is indeed any role at all—has
remained unresolved. A paper in this
issue of Cancer Cell from the Sawyers
laboratory (Mellinghoff et al., 2004) may
be a significant step toward understand-
ing the precise role of HER2 in prostatic
malignancy.
HER2 belongs to the ErbB class of
RTKs, of which the epidermal growth fac-
tor receptor (EGFR/ErbB1) is the found-
ing member. ErbB receptors form
signaling complexes by homo- and het-
erodimerizing within members of this
kinase family (Yarden and Sliwkowski,
2001). Although ErbB receptors are acti-
vated by EGF-like growth factors of sev-
eral kinds, HER2 is a ligandless receptor
that signals by avid association with
other ErbB RTKs activated by conven-
tional ligand binding. The promiscuous
nature of HER2 as a receptor dimeriza-
tion partner has been another major
rationale for studying it, the reasoning
being that if an ErbB receptor is process-
ing a signal, and sufficient levels of
HER2 are present, HER2 will be a partic-
ipant in the circuit.
Suspected ErbB receptor involve-
ment in prostate cancer originates partly
from the realization that these proteins
are capable of promoting the transcrip-
tional activity of the androgen receptor
(AR), a steroid hormone receptor
responsible for regulating genes involved
in masculinization and virilization. A hall-
mark of prostate cancer is its evolution
from an androgen-dependent to an
androgen-independent state. The AR is
now known to be involved in this transi-
tion to hormone independence, despite
the fact that androgen ablation therapy,
which removes the physiologic stimulus
for AR activation, is the mainstay of
prostate cancer treatment (Isaacs and
Isaacs, 2004). An example of this appar-
ent contradiction is the rise in circulating
levels of the androgen-dependent pro-
tein, prostate-specific antigen (PSA),
with hormone treatment failure, a
process that the AR is now believed to
mediate. The freeing of the AR from the
constraints imposed upon it by its normal
relationship with testicular androgens
and their derivatives allows the transcrip-
tion factor to stimulate gene expression
in a manner that promotes tumor cell
proliferation and survival.
AR activation by EGF and other
growth factors in a low-androgen envi-
ronment was first reported 10 years ago
(Culig et al., 1994) and has since been
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In this issue of Cancer Cell, Mellinghoff et al. (2004) demonstrate that a small molecule inhibitor of the EGF receptor (EGFR)
and the HER2/ErbB2/c-Neu kinase blocks signaling to the androgen receptor by a mechanism that involves HER2/HER3
heterodimerization. Surprisingly, the EGFR is peripheral to this signaling mechanism. These results have implications for
the design of targeted therapy for hormone-refractory prostate cancer.
Figure 1. Activation of the androgen receptor (AR) as a result of HER2/HER3 dimerization
HER/ErbB family receptor tyrosine kinases initiate intracellular signal transduction by dimerizing
with each other or with other members of the receptor family. Signaling cascades originating
from ErbB1/ErbB1 (1-1) and ErbB2/ErbB3 (2-3) dimers are shown, along with known protein inter-
mediates. The Mellinghoff et al. (2004) study in this issue of Cancer Cell demonstrates the exis-
tence of a signal from the 2-3 dimer to the AR, resulting in enhancement of AR-dependent,
hormone-independent signals. The paper presents evidence that the EGFR (participating in 1-
1, 1-2, or 1-3 dimers) or the serine-threonine kinase Akt/protein kinase B, which lies downstream
from the 2-3 dimer, are not involved in mediating this signaling mechanism. These findings indi-
cate that targeting the 2-3 dimer specifically may be a promising means of therapeutic inter-
vention in aggressive prostate cancer. The question mark indicates that the pathway from the
2-3 dimer to the AR was not identified. The ErbB3 icon has a cross in the cytoplasmic domain
because the intrinsic kinase is inactive. NRG, neuregulin, a growth factor capable of activating
the 2-3 dimer.
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verified by a number of groups. If we
accept the premise that ErbB receptors
activate AR without a need for the con-
ventional hormone, then we must ask
which ErbB proteins are the key villains.
This is more than academic, because the
various dimeric combinations of recep-
tors are believed to produce radically dif-
ferent downstream signals (Yarden and
Sliwkowski, 2001). For example, the
inclusion of HER3 in a dimerization com-
plex should be a potent activator of the
phosphoinositide-3-kinase (PI3K)→Akt
pathway because of a plethora of binding
sites for the PI3K p85 regulatory subunit
in the HER3 cytoplasmic domain.
The approach taken by Mellinghoff
and colleagues to the question of ErbB
involvement in prostate cancer was to
employ an EGFR/HER2 small molecule
inhibitor, PKI-166 (Bruns et al., 2000),
along with a series of pharmacologic and
genetic approaches in combination with
an array of in vitro and in vivo models.
These studies have resulted in two sur-
prising conclusions. First, the target for
PKI-166 inhibition of ErbB signaling to
the AR was found to be HER2, not
EGFR. The active signaling complex
inhibited by this drug was HER2/HER3,
which was shown to be capable of AR
activation in an androgen-depleted envi-
ronment. HER2/HER3 effects on AR
included effects on protein stability and
stimulation of DNA binding to AR target
genes. This is a novel insight that should
allow the development of a more focused
class of anti-prostate cancer agents,
which are inhibitors of the HER2/HER3
dimerization complex specifically (see
Figure 1). Another surprise was the find-
ing that the serine-threonine kinase
Akt/protein kinase B (PKB), which, in
principle, should lie immediately down-
stream of the HER2/HER3 dimer,
appears not to be involved in activation
of AR. This is potentially a critical insight
with respect to the molecular profiling of
prostate cancer tissues.
Analysis of clinical specimens with
antibodies directed against the phospho-
rylated activation residues of Akt has
provided strong evidence for the involve-
ment of this kinase family in prostate
cancer progression (Kreisberg et al.,
2004). Mechanisms known to activate
Akt include inactivation of the PI3K/Akt
pathway inhibitor, the lipid phosphatase
PTEN, as well as stimulation of upstream
signaling proteins, such as the ErbB pro-
teins and other RTKs. If the HER2/HER3
dimer does not activate AR through Akt,
then what is the consequence of activat-
ed Akt signaling in prostate cancer?
There are likely several answers to
this last question. From numerous stud-
ies on cells that do not express AR, it is
evident that Akt is quite capable of acting
on its own to stimulate cell growth and
survival mechanisms (Luo et al., 2003).
Although AR is present in most aggres-
sive prostate cancers, expression is
often heterogeneous, and inactivating
mutations may be common. Thus, Akt
activation may reflect a situation where
AR is bypassed rather than co-opted.
Alternatively, Akt and AR pathway sig-
nals may intersect in nefarious ways to
keep prostate cancer cells in the game in
the face of proapoptotic stimuli, such as
androgen withdrawal and chemotherapy.
Protein complexes containing AR and
Akt have been demonstrated by several
groups, and AR was shown to be phos-
phorylated by Akt on at least two
residues (Wen et al., 2000; Lin et al.,
2001), a result that is now somewhat
controversial for the endogenous protein
(Gioeli et al., 2002).
The Mellinghoff et al. study leaves for
another day the question of how we must
now visualize the role of the EGFR in
prostate cancer.The granddaddy of all of
the RTKs may have just been put out to
pasture in this disease. On the other
hand, the paper from the Sawyers group
is consistent with recent reports sug-
gesting that our appreciation of the role
of this protein in prostate cancer is sim-
ply maturing. Chronic EGFR activation
can lead to AR downmodulation and
functional attenuation under conditions
of robust tumor growth in a castrate envi-
ronment (Adam et al., 2002), suggesting
that the EGFR may be able to suppress
and consequently bypass AR while sup-
porting conditions that maintain the
growth potential of the tumor cell.
Consistent with this view, recent studies
have suggested that, while activation of
Akt may correlate with disease progres-
sion in prostate cancer, Erk MAPK acti-
vation may inversely correlate with
aggressive disease (Kreisberg et al.,
2004). Significantly, both pathways lie
downstream of the various ErbB dimers.
These observations suggest that RTKs
at the plasma membrane, as predicted
for many years, are critical sites for the
diversification of downstream signaling
in prostatic malignancy. The Mellinghoff
et al. study emphasizes the point that
investigators interested in developing
means of tumor profiling for directed
therapy or moving kinase inhibitors into
the clinical setting must take into account
the discrete mechanisms of upstream
activation, not just the downstream sig-
naling players, such as the MAPKs, Akt,
and other kinase pathways. This is
because not all ErbBs, and probably not
all RTKs, are cast from the same mold.
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